The approval of medicines called second-generation antipsychotics has allowed bipolar I and other associated conditions to be treated. A person with bipolar I disorder can go through various mood ...
AbbVie’s antipsychotic Vraylar could get a major boost from a potential expansion into depression. But like some other late-stage contenders, the drug’s clinical results fell short of a home run.
Reddit threads provide anecdotal information, which can be validating and comforting. But Vraylar’s prescribing information provides the clinical data. This article explores the most common questions ...
Vraylar may lead to mild side effects such as movement issues, restlessness, sleepiness, and weight gain, which are often temporary. Serious side effects may occur, including neuroleptic malignant ...
The approval of medicines called second-generation antipsychotics has allowed major depressive disorder (MDD) and other conditions linked to it to be treated. A person with MDD is usually prescribed ...
On Dec. 16, the U.S. Food and Drug Administration (FDA) gave AbbVie's (NYSE: ABBV) Vraylar the go-ahead as an adjunctive (add-on) treatment for patients with major depressive disorder (MDD). What was ...
AbbVie ABBV announced that the FDA has approved Vraylar (cariprazine) for the adjunctive treatment of patients with major depressive disorder (MDD). Vraylar is presently approved for treating ...
NEW ORLEANS -- Adjunctive cariprazine (Vraylar) was linked with a reduction in depressive symptoms for patients with major depressive disorder (MDD), who had an inadequate response to current therapy, ...
Allergan plc, a leading global pharmaceutical company, announced that the US Food and Drug Administration (FDA) has accepted for review the company's supplemental New Drug Application (sNDA) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results